Compare ORMP & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORMP | ANIK |
|---|---|---|
| Founded | 2002 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.3M | 200.9M |
| IPO Year | 2010 | 1996 |
| Metric | ORMP | ANIK |
|---|---|---|
| Price | $4.71 | $21.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | ★ 220.5K | 88.6K |
| Earning Date | 05-14-2026 | 04-29-2026 |
| Dividend Yield | ★ 6.51% | N/A |
| EPS Growth | ★ 412.50 | 80.16 |
| EPS | ★ 2.76 | N/A |
| Revenue | $2,000,000.00 | ★ $112,819,000.00 |
| Revenue This Year | N/A | $5.98 |
| Revenue Next Year | N/A | $7.42 |
| P/E Ratio | $1.69 | ★ N/A |
| Revenue Growth | ★ 49.25 | N/A |
| 52 Week Low | $2.09 | $8.56 |
| 52 Week High | $5.47 | $22.88 |
| Indicator | ORMP | ANIK |
|---|---|---|
| Relative Strength Index (RSI) | 48.89 | 57.47 |
| Support Level | $3.91 | $20.13 |
| Resistance Level | $5.10 | $22.70 |
| Average True Range (ATR) | 0.24 | 0.76 |
| MACD | -0.06 | -0.20 |
| Stochastic Oscillator | 8.43 | 61.41 |
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.